These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 16899108)

  • 101. The role of IL-6 in host defence against infections: immunobiology and clinical implications.
    Rose-John S; Winthrop K; Calabrese L
    Nat Rev Rheumatol; 2017 Jul; 13(7):399-409. PubMed ID: 28615731
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Antigen receptor signaling in the rheumatic diseases.
    Zikherman J; Weiss A
    Arthritis Res Ther; 2009; 11(1):202. PubMed ID: 19232064
    [TBL] [Abstract][Full Text] [Related]  

  • 103. [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].
    Frommer KW; Geyer M; Firestein GS
    Z Rheumatol; 2012 Aug; 71(6):460-7. PubMed ID: 22875571
    [TBL] [Abstract][Full Text] [Related]  

  • 104. IL-6 blockade for myocardial infarction.
    Iuchi A; Harada H; Tanaka T
    Int J Cardiol; 2018 Nov; 271():19-20. PubMed ID: 30482454
    [No Abstract]   [Full Text] [Related]  

  • 105. What is the role for interleukin-1 receptor antagonist in rheumatic disease?
    Lequerré T; Vittecoq O; le Loët X
    Joint Bone Spine; 2007 May; 74(3):223-6. PubMed ID: 17369070
    [No Abstract]   [Full Text] [Related]  

  • 106. Effects of Anti-Cytokine Antibodies on Gut Barrier Function.
    Liu F; Lee SA; Riordan SM; Zhang L; Zhu L
    Mediators Inflamm; 2019; 2019():7028253. PubMed ID: 31780866
    [TBL] [Abstract][Full Text] [Related]  

  • 107. The interleukin-6 pathway and atherosclerosis.
    Boekholdt SM; Stroes ES
    Lancet; 2012 Mar; 379(9822):1176-8. PubMed ID: 22421338
    [No Abstract]   [Full Text] [Related]  

  • 108. The interleukin 6 pathway and atherosclerosis.
    Scheller J; Rose-John S
    Lancet; 2012 Jul; 380(9839):338. PubMed ID: 22841333
    [No Abstract]   [Full Text] [Related]  

  • 109. Biologic activities of interleukin-1 relevant to rheumatic diseases.
    Miller LC; Dinarello CA
    Pathol Immunopathol Res; 1987; 6(1):22-36. PubMed ID: 3128783
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Rheumatic Immune-Related Adverse Events: Current Clinical Imperatives Underpin Future Novel Insights.
    Liew DFL; Meara AS
    Rheum Dis Clin North Am; 2024 May; 50(2):xvii-xix. PubMed ID: 38670733
    [No Abstract]   [Full Text] [Related]  

  • 111. Effects of inflammation on bone: an update.
    Baker-LePain JC; Nakamura MC; Lane NE
    Curr Opin Rheumatol; 2011 Jul; 23(4):389-95. PubMed ID: 21532485
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Review: Neutrophils as Invigorated Targets in Rheumatic Diseases.
    Grayson PC; Schauer C; Herrmann M; Kaplan MJ
    Arthritis Rheumatol; 2016 Sep; 68(9):2071-82. PubMed ID: 27159737
    [No Abstract]   [Full Text] [Related]  

  • 113. Strategies for the clinical development of anti-cytokines.
    Fenner H
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S183-4. PubMed ID: 8324946
    [No Abstract]   [Full Text] [Related]  

  • 114. Blocking interleukin-6 trans-signaling in AF: Promises and challenges.
    Martinez E; Li N
    Heart Rhythm; 2023 Dec; 20(12):1771-1772. PubMed ID: 37696442
    [No Abstract]   [Full Text] [Related]  

  • 115. IMprinting of PAthogenic Memory in Berlin.
    Romagnani C; Hauser A; Chang HD
    Eur J Immunol; 2013 Mar; 43(3):572-5. PubMed ID: 23607107
    [No Abstract]   [Full Text] [Related]  

  • 116. Interleukin-6 in the pathogenesis of rheumatoid arthritis.
    Park JY; Pillinger MH
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S4-10. PubMed ID: 17708744
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Evidence that cytokines play a role in rheumatoid arthritis.
    Brennan FM; McInnes IB
    J Clin Invest; 2008 Nov; 118(11):3537-45. PubMed ID: 18982160
    [TBL] [Abstract][Full Text] [Related]  

  • 118. The story of clobenpropit and CXCR4: can be an effective drug in cancer and autoimmune diseases?
    Abbasifard M; Bagherzadeh K; Khorramdelazad H
    Front Pharmacol; 2024; 15():1410104. PubMed ID: 39070795
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis.
    Bekaddour N; Smith N; Beitz B; Llibre A; Dott T; Baudry A; Korganow AS; Nisole S; Mouy R; Breton S; Bader-Meunier B; Duffy D; Terrier B; Schneider B; Quartier P; Rodero MP; Herbeuval JP
    Front Immunol; 2023; 14():1178172. PubMed ID: 37822935
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes.
    Xiao F; Wu L; Zhu X; Zhang L; Liu D; Wu L; Zou H; Lu L
    Rheumatol Immunol Res; 2022 Mar; 3(1):11-16. PubMed ID: 35772080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.